Combination therapy with an anti-hyaluronan agent and therapeutic agent
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/337
C12N-009/26
A61K-009/00
C12N-009/06
A61K-031/56
A61K-038/47
A61K-031/37
A61K-031/42
A61K-031/573
A61K-031/706
A61K-031/7068
A61K-031/7076
A61K-031/7088
A61K-045/06
A61K-047/60
A61K-047/56
A61K-047/64
A61K-047/48
출원번호
US-0625177
(2017-06-16)
등록번호
US-10137104
(2018-11-27)
발명자
/ 주소
Maneval, Daniel C.
Shepard, H. Michael
Thompson, Curtis B.
출원인 / 주소
Halozyme, Inc.
대리인 / 주소
Dentons US LLP
인용정보
피인용 횟수 :
0인용 특허 :
101
초록▼
Provided herein is combination cancer therapy effected by administering a polymer-conjugated hyaluronidase, and a tumor-targeted taxane, and optionally a further chemotherapeutic agent such as a nucleoside analog. The combination therapy can be used in methods of treating cancers, and in particular
Provided herein is combination cancer therapy effected by administering a polymer-conjugated hyaluronidase, and a tumor-targeted taxane, and optionally a further chemotherapeutic agent such as a nucleoside analog. The combination therapy can be used in methods of treating cancers, and in particular solid tumor cancers.
대표청구항▼
1. A method for treating pancreatic cancer, comprising administering to a subject: a) a composition comprising a soluble PH20 hyaluronidase, wherein the soluble PH20 hyaluronidase is PEGylated; andb) a composition comprising a tumor-targeted taxane that is nab-paclitaxel or nab-docetaxel, wherein: t
1. A method for treating pancreatic cancer, comprising administering to a subject: a) a composition comprising a soluble PH20 hyaluronidase, wherein the soluble PH20 hyaluronidase is PEGylated; andb) a composition comprising a tumor-targeted taxane that is nab-paclitaxel or nab-docetaxel, wherein: the subject has pancreatic cancer;the soluble PH20 hyaluronidase comprises a sequence of amino acid residues that has at least 95% sequence identity to the sequence of amino acid residues set forth in SEQ ID NO: 4; andthe composition comprising the PEGylated soluble PH20 hyaluronidase, and the composition comprising the tumor-targeted taxane are administered separately in two compositions or are administered in a single composition. 2. The method of claim 1, wherein the compositions are administered sequentially. 3. The method of claim 1, further comprising administering a composition comprising a nucleoside analog. 4. The method of claim 1, wherein the soluble PH20 hyaluronidase comprises a sequence of amino acids that has at least 98% sequence identity to the sequence set forth in SEQ ID NO: 4. 5. The method of claim 1, wherein: the hyaluronidase is a truncated PH20; andthe truncated PH20 comprises a sequence of amino acids that contains amino acids 36-464 of SEQ ID NO:1, or comprises a sequence of amino acids that has at least 95% sequence identity to a sequence of amino acids that contains at least amino acids 36-464 of SEQ ID NO:1 and retains hyaluronidase activity. 6. The method of claim 5, wherein the truncated PH20 comprises a sequence of amino acids set forth in any of SEQ ID NOS: 4-9, 47, 48, 150-170 or 183-189, or a sequence of amino acids that exhibits at least 98% sequence identity to a sequence of amino acids set forth in any of SEQ ID NOS: 4-9, 47, 48, 150-170 or 183-189 and retains hyaluronidase activity. 7. The method of claim 1, wherein the PEGylation moiety is a polyethylene glycol (PEG), and the PEG is a branched or linear PEG. 8. The method of claim 7, wherein the PEGylation moiety is selected from among methoxypolyethylene glycols (mPEGs). 9. The method of claim 1, wherein: the hyaluronidase is administered in a dosage range amount of between or about between 0.01 μg/kg to 15 μg/kg; orthe hyaluronidase is administered in a dosage range amount of between or about between 10 to 10,000 Units/kg (of the subject). 10. The method of claim 1, wherein: the tumor-targeted taxane is formulated as a delivery vehicle selected from among a micelle, nanoparticle, microsphere, liposomes or hydrogel; andthe delivery vehicle is linked directly or indirectly to a tumor-targeting moiety. 11. The method of claim 1, wherein the composition of b) comprises nab-docetaxel. 12. The method of claim 1, wherein the concentration of the taxane in composition b) is between about 0.01 mg taxane/mL to 100 mg/mL. 13. The method of claim 3, wherein the nucleoside analog is a purine or pyrimidine analog or derivatives thereof. 14. The method of claim 13, wherein the nucleoside analog is selected from among fluoropyrimidine 5-fluorouracil, 5-fluoro-2′-deoxycytidine, cytarabine, gemcitabine, troxacitabine, decitabine, Azacytidine, pseudoisocytidine, Zebularine, Ancitabine, Fazarabine, 6-azacytidine, capecitabine, N4-octadecyl-cytarabine, elaidic acid cytarabine, fludarabine, cladribine, clofarabine, nelarabine, forodesine, and pentostatin, or derivatives thereof. 15. The method of claim 3, wherein the nucleoside analog is administered in a dosage range that is between about 100 mg/m2 to 2500 mg/m2 body surface area of the subject. 16. The method of claim 1, wherein the composition(s) are administered orally, intravenously (IV), subcutaneously, intramuscularly, intra-tumorally, intradermally, topically, transdermally, rectally, intrathecally or sub-epidermally. 17. The method of claim 1, wherein the composition(s) is(are) administered intravenously or subcutaneously. 18. The method of claim 1, wherein the hyaluronidase is administered prior to, simultaneously, sequentially or intermittently with the tumor-targeted taxane. 19. The method of claim 18, wherein the hyaluronidase and tumor-targeted taxane are administered simultaneously or near simultaneously. 20. The method of claim 1, wherein: the frequency of administration of the hyaluronidase is twice weekly, once weekly, once every 14 days, once every 21 days or once every month; and/orthe frequency of administration of the tumor-targeted taxane is twice weekly, once weekly, once every 14 days, once every 21 days or once every month. 21. The method of claim 3, wherein the hyaluronidase and/or tumor-targeted taxane is administered prior to, simultaneously, sequentially, or intermittently with the nucleoside analog. 22. The method of claim 1, wherein the hyaluronidase and tumor-targeted taxane are administered for a predetermined number of weeks in a cycle of administration. 23. The method of claim 22, wherein the predetermined number of weeks is at least two weeks, at least three weeks or at least four weeks. 24. The method of claim 3, wherein the hyaluronidase and the tumor-targeted taxane are: administered prior to administration of the nucleoside analog;administered simultaneously; andadministered at a frequency of administration of twice weekly or once weekly for a predetermined number of weeks. 25. The method of claim 24, wherein the nucleoside analog is administered once weekly for a predetermined number of weeks. 26. The method of claim 24, wherein the hyaluronidase is administered twice weekly and the taxane is administered once weekly. 27. The method of claim 24, wherein the nucleoside analog is administered one week after administration of the hyaluronidase and the tumor-targeted taxane. 28. The method of claim 1, wherein the composition of b) comprises nab-paclitaxel. 29. The method of claim 1, wherein 30% or more of the tumoral area in a tumor biopsy from the subject expresses hyaluronan (HA). 30. The method of claim 29, wherein 50% or more of the tumoral area in the tumor biopsy expresses HA.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (101)
Wildfeuer Marvin E. (Lafayette IN), 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides.
Shepard, Harold Michael; Thompson, Curtis; Li, Xiaoming; Frost, Gregory I., Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects.
Kjell Douglas P. (West Lafayette IN), Catalytic stereoselective glycosylation process for preparing 2′-deoxy-2′,2′-difluoronucleosides and 2′-deoxy-2′-fl.
Pita Joe W. (880 NE. 75th St. Miami FL 33138) Mershon Scott (1009 Meridian Ave. ; #16 Miami Beach FL 33139) Muskat Michael A. (1230 95th St. Bay Harbor FL 33154), Chemiluminescent reactive vessel.
Studier F. William (Stony Brook NY) Davanloo Parichehre (Basel NY CHX) Rosenberg Alan H. (Setauket NY) Moffatt Barbara A. (East Lansing MI) Dunn John J. (Bellport NY), Cloning and expression of the gene for bacteriophage T7 RNA polymerase.
Oshlack Benjamin (New York NY) Chasin Mark (Manalapan NJ) Pedi ; Jr. Frank (Yorktown Heights NY), Controlled release formulations coated with aqueous dispersions of acrylic polymers.
Marshall Lucia G. I. (St. Charles MO) Patel Kanaiyalal R. (St. Louis MO) Roufa Dikla G. (St. Louis MO), Controlled release formulations of trophic factors in ganglioside-lipsome vehicle.
Stella Valentino J. (Lawrence KS) Mathew Abraham E. (Lenexa KS), Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof.
Bally Marcel B.,CAX ; Cullis Pieter R.,CAX ; Hope Michael J.,CAX ; Madden Thomas D.,CAX ; Mayer Lawrence D.,CAX, Encapsulation of antineoplastic agents in liposomes.
Nho, Kwang; Chang-min, Hyun; Lee, Jung-Hun; Kim, In-Kyung; Pak, Young-Kyoung, Hexa-arm polyethylene glycol and its derivatives and the methods of preparation thereof.
Frost, Gregory I.; Kundu, Anirban; Bookbinder, Louis H., Human chondroitinase glycoprotein (CHASEGP), process for preparing the same, and pharmaceutical compositions comprising thereof.
Stern Robert ; Frost Gregory I. ; Csoka Anthony ; Wong Tim M., Hybridoma cell lines producing monoclonal antibodies that bind to human plasma hyaluronidase.
Shaukat Ali ; J. Craig Franklin ; Imran Ahmad ; Eric Mayhew ; Soumendu Bhattacharya ; Gil Koehane ; Andrew S. Janoff, Hydrolysis-promoting hydrophobic taxane derivatives.
Shepard, H. Michael; Li, Xiaoming; Thompson, Curtis, Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods.
Harris J. Milton (Huntsville AL), Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for m.
Mohr Judy M. (Menlo Park CA) Baker Richard W. (Palo Alto CA) Nakaji Lisa A. (San Jose CA), Liquid reservoir transdermal patch for the administration of ketorolac.
Bartley Timothy D. ; Bogenberger Jakob M. ; Bosselman Robert A. ; Hunt Pamela ; Kinstler Olaf B. ; Samal Babru B., Method for treating mammals with monopegylated proteins that stimulates megakaryocyte growth and differentiation.
Desai Neil P. (Los Angeles CA) Soon-Shiong Patrick (Los Angeles CA) Sandford Paul A. (Los Angeles CA) Grinstaff Mark W. (Pasadena CA) Suslick Kenneth S. (Champaign IL), Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful th.
Bookbinder, Louis H.; Kundu, Anirban; Frost, Gregory I., Methods for treating a disease characterized by an excess of hyaluronan by administering a soluble hyaluronidase glycoprotein (sHASEGP).
Bartley Timothy D. ; Bogenberger Jakob M. ; Bosselman Robert A. ; Hunt Pamela ; Kinstler Olaf B. ; Samal Babru B., Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation.
Harris J. Milton ; Veronese Francesco Maria,ITX ; Caliceti Paolo,ITX ; Schiavon Oddone,ITX, Multiarmed, monofunctional, polymer for coupling to molecules and surfaces.
Davis Frank F. (19 Farmingdale Rd. East Brunswick NJ 08816) Van Es Theodorus (313 Overbrook Rd. Piscataway NJ 08854) Palczuk Nicholas C. (45 W. Franklin St. Bound Brook NJ 08805), Non-immunogenic polypeptides.
Santus Giancarlo (Milan ITX) Bilato Ettore (Padua ITX) Lazzarini Gabriele (Pero ITX), Pharmaceutical composition for the controlled release of moguisteine in a liquid suspension.
Le Grazie Cristina (Milan ITX), Pharmaceutical compositions containing 5-methyltetrahydrofolic acid, 5-formyltetrahydrofolic acid and their pharmaceutic.
Harris J. Milton (Huntsville AL) Kozlowski Antoni (Huntsville AL), Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives t.
Desai, Neil P.; Tao, Chunlin; Yang, Andrew; Louie, Leslie; Yao, Zhiwen; Soon-Shiong, Patrick; Magdassi, Shlomo, Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof.
Bookbinder, Louis H.; Kundu, Anirban; Frost, Gregory I., Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases.
Bookbinder, Louis H.; Kundu, Anirban; Frost, Gregory I., Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases.
Bookbinder, Louis H.; Kundu, Anirban; Frost, Gregory I., Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof.
Bookbinder, Louis H.; Kundu, Anirban; Frost, Gregory I., Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof.
Bookbinder, Louis H.; Kundu, Anirban; Frost, Gregory I., Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof.
Bookbinder, Louis H.; Kundu, Anirbau; Frost, Gregory I., Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof.
Bookbinder, Louis; Kundu, Anirban; Frost, Gregory I., Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof.
Chou Ta-Sen (Indianapolis IN) Poteet Laurie M. (Zionsville IN) Kjell Douglas P. (West Lafayette IN), Stereoselective glycosylation process for preparing 2\-Deoxy-2\, 2\-difluoronucleosides and 2\-deoxy-2\-fluoronucleoside.
Haugwitz Rudiger D. (Bethesda MD) Zalkow Leon (Atlanta GA) Glinski Jan (Ridgefield CT) Suffness Mathew (Silver Spring MD) Deutsch Howard M. (Atlanta GA) Narayanan Venkatachala (Gaithersburg MD), Water soluble, antineoplastic derivatives of taxol.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.